Article Dans Une Revue Journal for Immunotherapy of Cancer Année : 2019

Monalizumab: inhibiting the novel immune checkpoint NKG2A

Résumé

The implementation of immune checkpoint inhibitors to the oncology clinic signified a new era in cancer treatment. After the first indication of melanoma, an increasing list of additional cancer types are now treated with immune system targeting antibodies to PD-1, PD-L1 and CTLA-4, alleviating inhibition signals on T cells. Recently, we published proof-of-concept results on a novel checkpoint inhibitor, NKG2A. This receptor is expressed on cytotoxic lymphocytes, including NK cells and subsets of activated CD8(+) T cells. Blocking antibodies to NKG2A unleashed the reactivity of these effector cells resulting in tumor control in multiple mouse models and an early clinical trial. Monalizumab is inhibiting this checkpoint in human beings and future clinical trials will have to reveal its potency in combination with other cancer treatment options.

Domaines

Fichier principal
Vignette du fichier
40425_2019_Article_761.pdf (4.02 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)
Licence

Dates et versions

hal-02360854 , version 1 (16-11-2023)

Licence

Identifiants

Citer

Thorbald Van Hall, Pascale Andre, Amir Horowitz, Dan Fu Ruan, Linda Borst, et al.. Monalizumab: inhibiting the novel immune checkpoint NKG2A. Journal for Immunotherapy of Cancer, 2019, 7 (1), ⟨10.1186/s40425-019-0761-3⟩. ⟨hal-02360854⟩
115 Consultations
189 Téléchargements

Altmetric

Partager

  • More